Minerva Neurosciences (NERV) Stock Price, Quote, News & History | Benzinga

Minerva Neurosciences Inc (NERV) Stock Price, Quote, News & History

NERVNASDAQ

Trade with Public

Trade with Public

$6.83

-0.52-7.07%

At close: Apr 23, 5:00 PM EST

$7.77

0.9413.76%

After Hours: 9:27 AM EST

OverviewNews Earnings Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$7.34

Close

$6.83

Volume / Avg.

97.04K / 245.69K

Day Range

$6.83 - $7.42

52 Wk Range

1.30 - 12.46

Market Cap

$336.22M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

56

Short Interest

2.52%

Days to Cover

1.9

Recent Minerva Neurosciences Inc News

Minerva Stock Rises After Securing $200M for Schizophrenia Drug Trial

Minerva Neurosciences Inc (NASDAQ:NERV) shares are climbing Tuesday after the company announced up to $200 million in funding to support development of roluperidone for schizophrenia.

Evette Mitkov

Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.

Avi Kapoor

Regulatory Setback For Minerva Neurosciences' Schizophrenia Treatment Candidate, FDA Asks For More Data

Minerva Neurosciences faces FDA challenges for roluperidone in schizophrenia treatment. Understand the clinical deficiencies and potential paths forward. Cash position at December 31, 2023, around $41.0 million.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-13.51M

Investing Cash Flow (TTM)

0

Financing Cash Flow (TTM)

74.45M

Free Cash Flow (TTM)

-13.51M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

60.94M

Analyst Trends and Forecast

1

Nov 25

1

Mar

0

0

0

0

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$236.41M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-470.74%

Earnings Yield % (FWD)

-8.15%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$3.25

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$82.30M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$7.34

Close

$6.83

Volume / Avg.

97.04K / 245.69K

Day Range

$6.83 - $7.42

52 Wk Range

1.30 - 12.46

Market Cap

$336.22M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

56

Short Interest

2.52%

Days to Cover

1.9

About

Sector

Health Care

Industry

Biotechnology

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candid...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Minerva Neurosciences (NERV) stock?

A

You can purchase shares of Minerva Neurosciences (NASDAQ:NERV) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Minerva Neurosciences (NERV) competitors?

A

Other companies in Minerva Neurosciences’s space includes: Cabaletta Bio Inc (NASDAQ:CABA), Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL), Monopar Therapeutics Inc (NASDAQ:MNPR), DiaMedica Therapeutics Inc (NASDAQ:DMAC) and AC Immune SA (NASDAQ:ACIU).

Q

What is the forecast, or price target, for Minerva Neurosciences (NERV) stock?

A

Minerva Neurosciences has a consensus price target of $10.50.

Q

What is the current price for Minerva Neurosciences (NERV)?

A

The stock price for Minerva Neurosciences (NASDAQ: NERV) is $7.7696 last updated April 23, 2026 at 9:27 AM EDT.

Q

Does Minerva Neurosciences (NERV) pay a dividend?

A

There are no upcoming dividends for Minerva Neurosciences.

Q

When is Minerva Neurosciences (NASDAQ:NERV) reporting earnings?

A

Minerva Neurosciences does not have any upcoming earnings scheduled.

Q

Is Minerva Neurosciences (NERV) going to split?

A

There is no upcoming split for Minerva Neurosciences.

Q

What sector and industry does Minerva Neurosciences (NERV) operate in?

A

Minerva Neurosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Cabaletta Bio Inc

Zentalis Pharmaceuticals Inc

Monopar Therapeutics Inc

DiaMedica Therapeutics Inc

Eledon Pharmaceuticals Inc

Bicycle Therapeutics PLC

Abeona Therapeutics Inc